Clinical Trial Update: Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating extended-release niacin with laropiprant for lipid management in adults with primary hypercholesterolemia or mixed dyslipidemia has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Mixed Dyslipidemia

Drugs mentioned

• Cordaptive (niacin/laropiprant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Status: COMPLETED | Results posted: 2009-07-31